{"id":"docetaxel-cisplatin-5-fluorouracil","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"50-70%","effect":"Nausea and vomiting"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"30-50%","effect":"Fatigue"},{"rate":"10-30%","effect":"Mucositis"},{"rate":"70-90%","effect":"Hair loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Docetaxel binds to tubulin, preventing microtubule polymerization and cell division. Cisplatin forms platinum-DNA adducts, causing DNA damage and apoptosis. 5-Fluorouracil is converted to its active metabolite, which inhibits thymidylate synthase, leading to DNA synthesis inhibition and cell death.","oneSentence":"Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, and 5-fluorouracil inhibits thymidylate synthase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:42.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Non-small cell lung cancer"},{"name":"Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT02997332","phase":"PHASE1","title":"Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-03-30","conditions":"Head and Neck Cancers","enrollment":14},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT00707473","phase":"PHASE2","title":"Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-06-16","conditions":"Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Sinonasal Undifferentiated Carcinoma","enrollment":31},{"nctId":"NCT00588770","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-08","conditions":"Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":403},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT06952621","phase":"PHASE3","title":"Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2026-02-01","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":390},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT06839378","phase":"NA","title":"Flura-seq for Evaluating the Effects of Different Hyperthermic Intraperitoneal Chemotherapy Regimens on the Transcriptome of Pseudomyxoma Peritonei","status":"COMPLETED","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2025-02-17","conditions":"Pseudomyxoma Peritonei","enrollment":36},{"nctId":"NCT05494190","phase":"NA","title":"The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2022-11-01","conditions":"Hypopharyngeal Carcinoma","enrollment":111},{"nctId":"NCT01154920","phase":"PHASE2","title":"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":128},{"nctId":"NCT04854499","phase":"PHASE2","title":"Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-09-07","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":193},{"nctId":"NCT06699212","phase":"PHASE3","title":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases","status":"RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2024-12-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":412},{"nctId":"NCT03340896","phase":"PHASE3","title":"Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2015-06-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":256},{"nctId":"NCT06207981","phase":"PHASE3","title":"Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2024-02-26","conditions":"Anal Cancer","enrollment":310},{"nctId":"NCT04356170","phase":"PHASE2","title":"Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2021-02-04","conditions":"Cancer of Head and Neck","enrollment":105},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT00665392","phase":"PHASE2","title":"Cetuximab and Combination Chemotherapy in Patients With Stage III-IV Resectable Oropharynx Cancer","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2008-02-01","conditions":"Head and Neck Cancer","enrollment":42},{"nctId":"NCT03519295","phase":"PHASE2","title":"A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2018-07-03","conditions":"Anal Cancer","enrollment":97},{"nctId":"NCT06943820","phase":"PHASE1, PHASE2","title":"AK129 Combination Therapy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-05-21","conditions":"Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma","enrollment":230},{"nctId":"NCT03914443","phase":"PHASE1","title":"A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma","status":"COMPLETED","sponsor":"National Cancer Center, Japan","startDate":"2019-05-07","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT01924819","phase":"PHASE2, PHASE3","title":"Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":574},{"nctId":"NCT03574649","phase":"PHASE2","title":"QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-06","conditions":"Non Small Cell Lung Cancer","enrollment":""},{"nctId":"NCT00544414","phase":"PHASE2","title":"Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2000-06-07","conditions":"Head and Neck Cancer","enrollment":31},{"nctId":"NCT04544969","phase":"","title":"Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-04-01","conditions":"Circulating Tumor Cell, Nasopharyngeal Carcinoma, Distant Metastases.Clinical","enrollment":50},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT04649476","phase":"PHASE2","title":"Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Hospital of Stomatology, Wuhan University","startDate":"2021-03-22","conditions":"Oral Squamous Cell Carcinoma","enrollment":68},{"nctId":"NCT01286766","phase":"PHASE2","title":"Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":6},{"nctId":"NCT02723955","phase":"PHASE1","title":"Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-23","conditions":"Neoplasms","enrollment":829},{"nctId":"NCT04719988","phase":"PHASE2","title":"Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-01-04","conditions":"Squamous Cell Carcinoma of the Anus Stage III","enrollment":55},{"nctId":"NCT06713057","phase":"PHASE2","title":"Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-12-01","conditions":"Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer","enrollment":20},{"nctId":"NCT06714266","phase":"PHASE2","title":"Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-12-15","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":30},{"nctId":"NCT02009449","phase":"PHASE1","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11-15","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":353},{"nctId":"NCT04447352","phase":"PHASE3","title":"HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)","status":"RECRUITING","sponsor":"Krankenhaus Nordwest","startDate":"2020-12-17","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":200},{"nctId":"NCT00868491","phase":"PHASE2","title":"Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2008-03","conditions":"Head and Neck Cancer","enrollment":30},{"nctId":"NCT05517135","phase":"","title":"tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2022-11-17","conditions":"Nasopharyngeal Carcinoma","enrollment":1000},{"nctId":"NCT04747470","phase":"PHASE1","title":"Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-03-25","conditions":"Advanced Solid Tumors","enrollment":13},{"nctId":"NCT01404156","phase":"PHASE2, PHASE3","title":"Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Dr. Gordon Buduhan","startDate":"2015-09","conditions":"Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction","enrollment":29},{"nctId":"NCT04931420","phase":"PHASE2","title":"Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2022-05-19","conditions":"Metastatic Cancer, Foregut Carcinoid Tumor, Gastric Adenocarcinoma","enrollment":""},{"nctId":"NCT06463834","phase":"PHASE2","title":"A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-03-20","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT03326947","phase":"PHASE2","title":"Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-01-01","conditions":"Neoplasm Neck","enrollment":60},{"nctId":"NCT00502463","phase":"NA","title":"Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial","status":"COMPLETED","sponsor":"Austrian South Oncology Group","startDate":"2007-10-03","conditions":"Head and Neck Cancer","enrollment":51},{"nctId":"NCT04894370","phase":"PHASE2","title":"Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-06-09","conditions":"Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma","enrollment":34},{"nctId":"NCT06156878","phase":"PHASE2","title":"PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":41},{"nctId":"NCT05125055","phase":"PHASE2, PHASE3","title":"Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-10-01","conditions":"Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1","enrollment":80},{"nctId":"NCT02290145","phase":"PHASE2","title":"Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-12","conditions":"Mouth Neoplasms, Carcinoma, Squamous Cell","enrollment":48},{"nctId":"NCT02285543","phase":"PHASE2","title":"A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients","status":"TERMINATED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-12-01","conditions":"Mouth Neoplasms, Carcinoma, Squamous Cell","enrollment":10},{"nctId":"NCT06102395","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2023-05-01","conditions":"Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab","enrollment":272},{"nctId":"NCT01914900","phase":"PHASE2","title":"Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2012-06","conditions":"Locally Advanced Resectable Oral Cavity Squamous Cell Cancer","enrollment":14},{"nctId":"NCT05116891","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Cantargia AB","startDate":"2021-09-22","conditions":"Advanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT02484677","phase":"PHASE4","title":"Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2015-07-15","conditions":"Patients With Head and Neck Cancer (ORL)","enrollment":12},{"nctId":"NCT05860868","phase":"PHASE3","title":"Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2023-05","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":474},{"nctId":"NCT02285530","phase":"PHASE2","title":"GDF15 Based TPF Induction Chemotherapy for OSCC Patients","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2019-12-01","conditions":"Mouth Neoplasms, Carcinoma, Squamous Cell","enrollment":72},{"nctId":"NCT02099175","phase":"PHASE2","title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2013-11","conditions":"Sinonasal Tumors","enrollment":41},{"nctId":"NCT02099188","phase":"PHASE2","title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2013-11","conditions":"Unresectable Sinonasal Tumors","enrollment":27},{"nctId":"NCT05151588","phase":"PHASE2","title":"Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Dr. Victor H.F. Lee","startDate":"2023-09-01","conditions":"Sinonasal Carcinoma","enrollment":30},{"nctId":"NCT01726452","phase":"PHASE3","title":"NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2013-01-24","conditions":"Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Oesophago-gastric Junction, Oesophageal Tumours","enrollment":377},{"nctId":"NCT02268695","phase":"PHASE2","title":"Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2014-10-10","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":541},{"nctId":"NCT05235542","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors","status":"UNKNOWN","sponsor":"Akeso","startDate":"2022-07-12","conditions":"Advanced Malignant Tumors","enrollment":130},{"nctId":"NCT04849377","phase":"PHASE2","title":"RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC","status":"WITHDRAWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2022-06-14","conditions":"Human Papillomavirus (HPV), Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":""},{"nctId":"NCT01884259","phase":"PHASE2","title":"Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2013-05","conditions":"Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Squamous Cell Carcinoma of the Larynx Stage III","enrollment":100},{"nctId":"NCT02402842","phase":"PHASE2","title":"Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2014-09","conditions":"Anal Canal Carcinoma","enrollment":70},{"nctId":"NCT04437329","phase":"PHASE3","title":"Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2020-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":352},{"nctId":"NCT04508829","phase":"PHASE2","title":"Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2016-01-01","conditions":"Oropharyngeal Carcinoma","enrollment":52},{"nctId":"NCT01889303","phase":"PHASE2","title":"Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Wuhan University","startDate":"2013-05","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT05062005","phase":"PHASE3","title":"ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2021-09-22","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":447},{"nctId":"NCT00896181","phase":"PHASE2","title":"Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2008-12-10","conditions":"Stage II Lymphoepithelioma of the Nasopharynx, Stage II Squamous Cell Carcinoma of the Nasopharynx, Stage III Lymphoepithelioma of the Nasopharynx","enrollment":26},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT04764149","phase":"","title":"Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-11-01","conditions":"Nasopharyngeal Carcinoma","enrollment":801},{"nctId":"NCT04595929","phase":"NA","title":"Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2020-02-10","conditions":"Peritoneal Carcinomatosis, Gastric Cancer","enrollment":304},{"nctId":"NCT02640898","phase":"NA","title":"Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy Compared With INT 0116 Adjuvant Arm in Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2015-12","conditions":"Gastric Cancer","enrollment":500},{"nctId":"NCT04502641","phase":"PHASE3","title":"Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-08-01","conditions":"Hypopharyngeal Cancer","enrollment":160},{"nctId":"NCT04472403","phase":"","title":"Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-11-26","conditions":"Nasopharyngeal Carcinoma, Metastasis, Chemotherapy","enrollment":2000},{"nctId":"NCT04414566","phase":"PHASE3","title":"Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2020-06-01","conditions":"Nasopharyngeal Carcinoma","enrollment":562},{"nctId":"NCT04397341","phase":"PHASE2","title":"Biweekly TPF Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of Head and Neck","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2014-03-01","conditions":"Locally Advanced Head and Neck Carcinoma","enrollment":58},{"nctId":"NCT00721513","phase":"PHASE2","title":"Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2008-09","conditions":"Head and Neck Cancer","enrollment":20},{"nctId":"NCT03389295","phase":"PHASE2","title":"Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Xiayun He, MD","startDate":"2010-01","conditions":"Nasopharyngeal Carcinoma","enrollment":118},{"nctId":"NCT00515411","phase":"PHASE2","title":"Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-10-23","conditions":"Gastroesophageal Junction Adenocarcinoma, Gastric Cancer","enrollment":111},{"nctId":"NCT01312350","phase":"PHASE2","title":"Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2010-11","conditions":"Hypopharyngeal Cancer","enrollment":40},{"nctId":"NCT02721576","phase":"PHASE4","title":"A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC","status":"TERMINATED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2016-07-05","conditions":"Esophageal Neoplasms","enrollment":8},{"nctId":"NCT02721563","phase":"PHASE4","title":"A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC","status":"COMPLETED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2016-02-25","conditions":"Esophageal Neoplasms","enrollment":77},{"nctId":"NCT02721550","phase":"PHASE4","title":"A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC","status":"TERMINATED","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2016-08-01","conditions":"Esophageal Neoplasms","enrollment":2},{"nctId":"NCT01216644","phase":"PHASE2, PHASE3","title":"5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer","status":"COMPLETED","sponsor":"Krankenhaus Nordwest","startDate":"2010-08","conditions":"Gastric Cancer","enrollment":716},{"nctId":"NCT00716391","phase":"PHASE3","title":"TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.","status":"COMPLETED","sponsor":"Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","startDate":"2008-07-07","conditions":"Head and Neck Cancer","enrollment":519},{"nctId":"NCT01248299","phase":"PHASE2","title":"Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2011-01","conditions":"Squamous Cell Carcinoma of Esophagus","enrollment":105},{"nctId":"NCT00765011","phase":"PHASE2","title":"TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer","status":"COMPLETED","sponsor":"Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","startDate":"2008-10","conditions":"Head and Neck Cancer","enrollment":94},{"nctId":"NCT02012062","phase":"PHASE3","title":"Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC","status":"COMPLETED","sponsor":"Fudan University","startDate":"2012-07","conditions":"Nasopharyngeal Carcinoma","enrollment":160},{"nctId":"NCT03114280","phase":"PHASE1, PHASE2","title":"Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)","status":"WITHDRAWN","sponsor":"Centre Antoine Lacassagne","startDate":"2019-03-12","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":""},{"nctId":"NCT01715233","phase":"PHASE2","title":"Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2012-12","conditions":"Metastatic Esophageal Cancer, Gastroesophageal Cancer, Gastric Cancer","enrollment":27},{"nctId":"NCT00169182","phase":"PHASE3","title":"Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2001-12-15","conditions":"Larynx Cancer, Hypopharynx Cancer","enrollment":220},{"nctId":"NCT01181401","phase":"PHASE2","title":"InductionChemo-Radio-Antibody-Treatment","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2010-08","conditions":"Squamous Cell Carcinoma of the Head, Squamous Cell Carcinoma of the Neck","enrollment":94},{"nctId":"NCT01283204","phase":"PHASE2","title":"Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-03-09","conditions":"Recurrent or Metastatic Gastric Cancer","enrollment":180},{"nctId":"NCT01233843","phase":"PHASE3","title":"Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.","status":"COMPLETED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2009-05-18","conditions":"Squamous Cell Head and Neck Carcinoma","enrollment":370},{"nctId":"NCT00828386","phase":"PHASE3","title":"Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers","status":"TERMINATED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2009-01","conditions":"Nasopharyngeal Cancers","enrollment":83},{"nctId":"NCT03723343","phase":"","title":"GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-10-18","conditions":"Advanced Nasopharyngeal Carcinoma","enrollment":146},{"nctId":"NCT02358863","phase":"NA","title":"Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2015-02","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":13},{"nctId":"NCT01608464","phase":"PHASE2","title":"Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer","status":"TERMINATED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2012-05","conditions":"Carcinoma of Esophagus","enrollment":170},{"nctId":"NCT03604965","phase":"PHASE3","title":"GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-07-21","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":204},{"nctId":"NCT00003888","phase":"PHASE3","title":"Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1999-04","conditions":"Head and Neck Cancer","enrollment":359},{"nctId":"NCT03574324","phase":"PHASE3","title":"TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-05-24","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":266}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":109,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"docetaxel - cisplatin - 5-fluorouracil","genericName":"docetaxel - cisplatin - 5-fluorouracil","companyName":"Gruppo Oncologico del Nord-Ovest","companyId":"gruppo-oncologico-del-nord-ovest","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, and 5-fluorouracil inhibits thymidylate synthase. Used for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}